| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/12/2002 | US6355445 Bacteriophage coupling to enzyme |
| 03/12/2002 | US6355444 Detecting cancer marker in sample; obtain hybridoma sample, incubate with antibody, detect bound antibody |
| 03/12/2002 | US6355440 Detecting cell growth factors in sample; mix target sample with preferential receptors, detect binding, bound receptor indicates presence of cell growth factor in sample |
| 03/12/2002 | US6355426 Methods for the characterization and selection of RNA target motifs that bind compounds of pharmaceutical use |
| 03/12/2002 | US6355271 Mixing an aqueous solution of calcium chloride with an aqueous solution of sodium citrate to form a mixture, adding an aqueous solution of sodium phosphate to the mixture to form a solution, stirring the solution |
| 03/12/2002 | US6355270 Particles for oral delivery of peptides and proteins |
| 03/12/2002 | US6355258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form |
| 03/12/2002 | US6355255 Streptococcal C5a peptidase vaccine |
| 03/12/2002 | US6355254 Pathogenic Escherichia coli associated protein EspA |
| 03/12/2002 | US6355252 Antiinflammatory agents |
| 03/12/2002 | US6355248 Method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
| 03/12/2002 | US6355245 Glomerulonephritis,antibodies at low dosage |
| 03/12/2002 | US6355243 Method of thrombolysis by local delivery of active plasmin |
| 03/12/2002 | US6355242 Materials and methods for treating or preventing oxalate-related disease |
| 03/12/2002 | US6355241 In vivo production and delivery of erythropoietin |
| 03/12/2002 | US6355238 Specific immune system modulation |
| 03/12/2002 | US6355237 Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| 03/12/2002 | US6355228 Oral care product comprising a mutan binding domain |
| 03/12/2002 | CA2235625C Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation |
| 03/12/2002 | CA2189657C Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody |
| 03/12/2002 | CA2064077C T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| 03/12/2002 | CA2053799C Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
| 03/12/2002 | CA2034741C Therapeutic antibody based fusion proteins |
| 03/12/2002 | CA2016235C Labeled chemotactic peptides to image focal sites of infection or inflammation |
| 03/12/2002 | CA1341347C Androgen receptor proteins, recombinant dna molecules coding for such, and use of such compositions |
| 03/07/2002 | WO2002018954A2 Inhibition of cmv infection and dissemination |
| 03/07/2002 | WO2002018938A1 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| 03/07/2002 | WO2002018637A2 Diagnosis and treatment of prostate cancer |
| 03/07/2002 | WO2002018626A1 Modulators of the interaction between arp2/3 and cortactin or hs-1 |
| 03/07/2002 | WO2002018623A2 Methods and reagents for protease inhibition |
| 03/07/2002 | WO2002018622A2 TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b) |
| 03/07/2002 | WO2002018608A2 Methods for enhancing the efficacy of cancer therapy |
| 03/07/2002 | WO2002018604A2 Methods and compositions for determining isomerase enzymatic activity |
| 03/07/2002 | WO2002018593A2 Modulation of fas and fasl expression |
| 03/07/2002 | WO2002018585A2 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | WO2002018584A2 Xage-1, a gene expressed in multiple cancers, and uses thereof |
| 03/07/2002 | WO2002018583A2 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 03/07/2002 | WO2002018582A2 62112, a novel human dehydrogenase and uses thereof |
| 03/07/2002 | WO2002018581A2 G-protein coupled receptors |
| 03/07/2002 | WO2002018579A2 57242, a novel human g protein-coupled receptor family member and uses therefor |
| 03/07/2002 | WO2002018577A2 48921, a novel human gtp releasing factor and uses therefor |
| 03/07/2002 | WO2002018575A2 Genes expressed in the cell cycle |
| 03/07/2002 | WO2002018574A2 Human interleukin-four induced protein |
| 03/07/2002 | WO2002018573A2 54370, a novel human sulfate transporter and uses therefor |
| 03/07/2002 | WO2002018572A2 Membrane penetrating peptides and uses thereof |
| 03/07/2002 | WO2002018568A2 Molecules involved in the regulation of insulin in resistance syndrome (irs) |
| 03/07/2002 | WO2002018565A2 Regulation of human protein phosphatase iic-like enzyme |
| 03/07/2002 | WO2002018556A2 8797, a human galactosyltransferase and uses thereof |
| 03/07/2002 | WO2002018555A2 Human kinase proteins and polynucleotides encoding the same |
| 03/07/2002 | WO2002018554A2 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 03/07/2002 | WO2002018552A2 Regulation of human aminotransferase-like enzyme |
| 03/07/2002 | WO2002018548A2 Tyrosine hydroxylase 5' control elements and uses thereof |
| 03/07/2002 | WO2002018544A2 Method and reagents for treatment of skin disorders by modulating the notch pathway |
| 03/07/2002 | WO2002018536A2 Truncated bard1 protein, and its diagnostic and therapeutic uses |
| 03/07/2002 | WO2002018450A1 New cross-linked derivatives of hyaluronic acid |
| 03/07/2002 | WO2002018448A2 Percarboxylated polysaccharides, and a process for their preparation |
| 03/07/2002 | WO2002018446A2 Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins |
| 03/07/2002 | WO2002018444A2 Erbb4 antagonists |
| 03/07/2002 | WO2002018441A2 Electroprocessed fibrin-based matrices and tissues |
| 03/07/2002 | WO2002018440A1 Anti-angiogenic peptides |
| 03/07/2002 | WO2002018439A2 52991, a human transporter protein and uses therefor |
| 03/07/2002 | WO2002018438A1 Modified proteins, isolated novel peptides, and uses thereof |
| 03/07/2002 | WO2002018437A2 Cyclic peptides having melanocortin-4 receptor agonist activity |
| 03/07/2002 | WO2002018436A1 Product and method for control of obesity |
| 03/07/2002 | WO2002018435A1 18 human secreted proteins |
| 03/07/2002 | WO2002018433A1 Adhesive protein and uses thereof |
| 03/07/2002 | WO2002018432A2 Protein extracted from the intestines of vertebrates, which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport |
| 03/07/2002 | WO2002018427A2 Nucleotide sequences which code for the cita gene |
| 03/07/2002 | WO2002018425A2 '47324', a novel g-protein and uses therefor |
| 03/07/2002 | WO2002018424A2 Nucleic acids and polypeptides |
| 03/07/2002 | WO2002018423A1 Bioactive peptide for cell adhesion |
| 03/07/2002 | WO2002018422A1 Amino acid substitution mutants of interleukin 13 |
| 03/07/2002 | WO2002018412A1 17 human secreted proteins |
| 03/07/2002 | WO2002018409A1 Antisense modulation of hpk/gck-like kinase expression |
| 03/07/2002 | WO2002018378A1 Pyrrolidine derivatives and their use as chymase inhibitor |
| 03/07/2002 | WO2002018369A2 Peptidomimetic protease inhibitors |
| 03/07/2002 | WO2002018341A2 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | WO2002017968A2 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| 03/07/2002 | WO2002017965A1 Medicinal compositions |
| 03/07/2002 | WO2002017964A1 The synergetic effects of hgf and antibacterial treatment |
| 03/07/2002 | WO2002017963A2 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 03/07/2002 | WO2002017959A2 Immunosuppression using piceatannol and a calcineurin inhibitor |
| 03/07/2002 | WO2002017958A1 Agent for influencing angiogenesis |
| 03/07/2002 | WO2002017956A2 Stabilized fgf formulations containing reducing agents |
| 03/07/2002 | WO2002017955A1 Delivery system for heparin-binding growth factors |
| 03/07/2002 | WO2002017954A1 Antiparkinsonism drugs |
| 03/07/2002 | WO2002017953A2 Thrombomodulin analogs for use in recovery of signal cord injury |
| 03/07/2002 | WO2002017952A2 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| 03/07/2002 | WO2002017951A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | WO2002017950A2 Detecting and influencing the expression or function of cd95/cd95l in infections |
| 03/07/2002 | WO2002017949A2 Novel functions for dp214 |
| 03/07/2002 | WO2002017948A2 Control of crop pests and animal parasites through direct neuronal uptake |
| 03/07/2002 | WO2002017947A2 Use of t proteins for the differential characterization and treatment of lesions and tumors of the nervous system |
| 03/07/2002 | WO2002017946A1 Bioactive fraction of eurycoma longifolia |
| 03/07/2002 | WO2002017936A1 Methods for processing animal tissues |
| 03/07/2002 | WO2002017924A1 Method of treatment |
| 03/07/2002 | WO2002017901A2 Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
| 03/07/2002 | WO2002017899A2 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| 03/07/2002 | WO2002017898A2 Compositions and methods for inducing vasorelaxation |
| 03/07/2002 | WO2002017893A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets |